Argenx $ARGX sinks 14% after an independent safety panel recommends halting its Phase 3 Sjögren’s study. Interim data showed the drug unlikely to hit its primary endpoint, the trial’s main goal. A celiac Phase 2 win didn’t help. @petenajarian @jonnajarian dissect the data because #ITSNOTANOPTION 📙 RebelCon 2026 Oct 19-21 Vegas 👉 https://t.co/3C7PXfRfl5
View on X ↗